Effect of Anti-CD20 Monoclonal Antibody (Rituximab) on Recalcitrant Pemphigus Vulgaris / 대한피부과학회지
Korean Journal of Dermatology
;
: 319-324, 2008.
Article
Dans Coréen
| WPRIM
| ID: wpr-204122
ABSTRACT
BACKGROUND:
Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus.OBJECTIVE:
The purpose of this study was to evaluate the efficacy and safety of Rituximab in the treatment of refractory pemphigus vulgaris.METHODS:
A retrospective analysis was conducted of six patients with recalcitrant pemphigus vulgaris in Yongdong Severance Hospital. Rituximab was administered intravenously at a dosage of 375 mg/m(2) body surface area. Five patient received 2 cycles of Rituximab treatment with an interval of 7 days. One patient received 5 cycles of treatment. The mean follow-up after treatment was 9.3 months (range, 2 months to 16 months).RESULTS:
All the patients presented clinical improvements. The average pemphigus vulgaris severity score decreased from 12.2 to 2.5 after treatment. No adverse effects were observed.CONCLUSION:
Rituximab has been proved as an effective and safe treatment for refractory pemphigus vulgaris.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Autoanticorps
/
Surface corporelle
/
Lymphocytes B
/
Études rétrospectives
/
Études de suivi
/
Cloque
/
Pemphigus
/
Antigènes CD20
/
Desmogléines
/
Anticorps monoclonaux d'origine murine
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Korean Journal of Dermatology
Année:
2008
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS